Shots :
- Daiichi reported the first patient dosing in a P-III (DESTINY-Endometrial01) study evaluating ENHERTU (trastuzumab deruxtecan) + rilvegostomig or pembrolizumab vs Pt. chemotx. (carboplatin and paclitaxel) + pembrolizumab as 1L therapy, in HER2-expressing (IHC 3+/2+), pMMR advanced or recurrent endometrial cancer pts
- The study is assessing the efficacy and safety of ENHERTU (5.4 mg/kg) and will enroll ~600 pts across multiple sites in Asia, Europe, North America, Oceania, and South America. The study 1EP is PFS assessed by BICR while the key 2EP is OS. Additional 2EPs include investigator-assessed PFS, ORR, DOR, and safety
- The P-III (DESTINY-Endometrial01) study will be conducted in collaboration with GOG-Foundation and the ENGOT
Ref: Businesswire| Image: Daiichi Sankyo | Press Release
Related News:- Italfarmaco Obtains the EC’s Conditional Approval for Duvyzat to Treat Duchenne Muscular Dystrophy (DMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
